Utilization and efficacy of second-line targeted therapy in
metastatic renal cell carcinoma: data from a national registry

J 2017

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

LAKOMÝ, Radek, Alexandr POPRACH, Zbyněk BORTLÍČEK, B. MELICHAR, Renata CHLOUPKOVÁ et. al.

Basic information

Original name

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

Authors

LAKOMÝ, Radek (203 Czech Republic, guarantor, belonging to the institution), Alexandr POPRACH (203 Czech Republic, belonging to the institution), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), B. MELICHAR (203 Czech Republic), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Rostislav VYZULA (203 Czech Republic, belonging to the institution), M. ZEMANOVA (203 Czech Republic), K. KOPECKOVA (203 Czech Republic), Marek SVOBODA (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution), Igor KISS (203 Czech Republic, belonging to the institution), H. STUDENTOVA (203 Czech Republic), Jaroslav JURÁČEK (203 Czech Republic, belonging to the institution), O. FIALA (203 Czech Republic), J. KOPECKY (203 Czech Republic), J. FINEK (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Karel HEJDUK (203 Czech Republic, belonging to the institution) and T. BUCHLER (203 Czech Republic)

Edition

BMC Cancer, London, BioMed Central, 2017, 1471-2407

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.288

RIV identification code

RIV/00216224:14110/17:00095691

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1186/s12885-017-3901-5

UT WoS

000418719700004

Keywords in English

Renal cell carcinoma; Therapy; Sunitinib; Sorafenib; Everolimus; Pazopanib

Abstract

V originále

Background: It is well known that patient characteristics and survival outcomes in randomized trials may not necessarily be similar to those in real-life clinical practice. The aim of the present study was to analyse second line treatment strategies in the real-world practice and to estimate the outcomes of patients treated with second-line targeted therapy for metastatic renal cell carcinoma (mRCC). Methods: This is a retrospective, registry-based study using data from the national registry of targeted therapies for mRCC. The RENIS registry contains data on 3049 patients who started the therapy with at least one targeted agent before 31 December, 2014. Of these patients, 1029 had a record of at least two different targeted therapies and sufficient data for analysis. Survival analysis was carried out using the Kaplan-Meier method. Statistical significance of differences in survival between subgroups was assessed using the log-rank test. Results: The median overall survival from the start of second-line treatment was 17.0 months (95% confidence interval [CI] 14.5-19.5 months), 17.1 months (95% CI 14.5-19.8), and 15.4 months (95% CI 11.0-19.7) for second-line everolimus, sorafenib, and sunitinib, respectively. Patients receiving second-line everolimus were older at the start of second-line treatment, more likely to have metachronous disease, and less likely to be previously treated with cytokines or to continue to third-line treatment than patients treated with second-line sunitinib or sorafenib. Progression-free survival (PFS) correlated with PFS on first-line treatment only for everolimus. Conclusions: In this retrospective study, no significant differences in survival were observed between the cohorts treated with different second-line agents including everolimus, sorafenib, and sunitinib.

Links

ED1.1.00/02.0068, research and development project

Name: CEITEC - central european institute of technology

NT13547, research and development project

Name: Studium mikroRNA a genů asociovaných s procesem epiteliálně-mezenchymální tranzice jako potenciálních markerů pro predikci rizika a časný záchyt metastazování u pacientů s renálním karcinomem

NV15-34678A, research and development project

Name: Molekulární prognostické a prediktivní faktory u pacientů s metastatickým renálním karcinomem léčených tyrozinkinázovými inhibitory

90004, large research infrastructures

Name: BBMRI-CZ

Citovat

LAKOMÝ, Radek, Alexandr POPRACH, Zbyněk BORTLÍČEK, B. MELICHAR, Renata CHLOUPKOVÁ, Rostislav VYZULA, M. ZEMANOVA, K. KOPECKOVA, Marek SVOBODA, Ondřej SLABÝ, Igor KISS, H. STUDENTOVA, Jaroslav JURÁČEK, O. FIALA, J. KOPECKY, J. FINEK, Ladislav DUŠEK, Karel HEJDUK and T. BUCHLER. Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. BMC Cancer. London: BioMed Central, 2017, vol. 17, No 880, p. 1-8. ISSN 1471-2407. Available from: https://dx.doi.org/10.1186/s12885-017-3901-5.

@article{1402032,
   author = {Lakomý, Radek and Poprach, Alexandr and Bortlíček, Zbyněk and Melichar, B. and Chloupková, Renata and Vyzula, Rostislav and Zemanova, M. and Kopeckova, K. and Svoboda, Marek and Slabý, Ondřej and Kiss, Igor and Studentova, H. and Juráček, Jaroslav and Fiala, O. and Kopecky, J. and Finek, J. and Dušek, Ladislav and Hejduk, Karel and Buchler, T.},
   article_location = {London},
   article_number = {880},
   doi = {http://dx.doi.org/10.1186/s12885-017-3901-5},
   keywords = {Renal cell carcinoma; Therapy; Sunitinib; Sorafenib; Everolimus; Pazopanib},
   language = {eng},
   issn = {1471-2407},
   journal = {BMC Cancer},
   title = {Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry},
   url = {https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3901-5},
   volume = {17},
   year = {2017}
}

TY  - JOUR
ID  - 1402032
AU  - Lakomý, Radek - Poprach, Alexandr - Bortlíček, Zbyněk - Melichar, B. - Chloupková, Renata - Vyzula, Rostislav - Zemanova, M. - Kopeckova, K. - Svoboda, Marek - Slabý, Ondřej - Kiss, Igor - Studentova, H. - Juráček, Jaroslav - Fiala, O. - Kopecky, J. - Finek, J. - Dušek, Ladislav - Hejduk, Karel - Buchler, T.
PY  - 2017
TI  - Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
JF  - BMC Cancer
VL  - 17
IS  - 880
SP  - 1-8
EP  - 1-8
PB  - BioMed Central
SN  - 14712407
KW  - Renal cell carcinoma
KW  - Therapy
KW  - Sunitinib
KW  - Sorafenib
KW  - Everolimus
KW  - Pazopanib
UR  - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3901-5
N2  - Background: It is well known that patient characteristics and survival outcomes in randomized trials may not necessarily be similar to those in real-life clinical practice. The aim of the present study was to analyse second line treatment strategies in the real-world practice and to estimate the outcomes of patients treated with second-line targeted therapy for metastatic renal cell carcinoma (mRCC). Methods: This is a retrospective, registry-based study using data from the national registry of targeted therapies for mRCC. The RENIS registry contains data on 3049 patients who started the therapy with at least one targeted agent before 31 December, 2014. Of these patients, 1029 had a record of at least two different targeted therapies and sufficient data for analysis. Survival analysis was carried out using the Kaplan-Meier method. Statistical significance of differences in survival between subgroups was assessed using the log-rank test. Results: The median overall survival from the start of second-line treatment was 17.0 months (95% confidence interval [CI] 14.5-19.5 months), 17.1 months (95% CI 14.5-19.8), and 15.4 months (95% CI 11.0-19.7) for second-line everolimus, sorafenib, and sunitinib, respectively. Patients receiving second-line everolimus were older at the start of second-line treatment, more likely to have metachronous disease, and less likely to be previously treated with cytokines or to continue to third-line treatment than patients treated with second-line sunitinib or sorafenib. Progression-free survival (PFS) correlated with PFS on first-line treatment only for everolimus. Conclusions: In this retrospective study, no significant differences in survival were observed between the cohorts treated with different second-line agents including everolimus, sorafenib, and sunitinib.
ER  -

LAKOMÝ, Radek, Alexandr POPRACH, Zbyněk BORTLÍČEK, B. MELICHAR, Renata CHLOUPKOVÁ, Rostislav VYZULA, M. ZEMANOVA, K. KOPECKOVA, Marek SVOBODA, Ondřej SLABÝ, Igor KISS, H. STUDENTOVA, Jaroslav JURÁČEK, O. FIALA, J. KOPECKY, J. FINEK, Ladislav DUŠEK, Karel HEJDUK and T. BUCHLER. Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. \textit{BMC Cancer}. London: BioMed Central, 2017, vol.~17, No~880, p.~1-8. ISSN~1471-2407. Available from: https://dx.doi.org/10.1186/s12885-017-3901-5.

Detailed Information on Publication Record